Higashi Study Highlights & Related Information

A randomized, double-blind, parallel-group, placebo-controlled, multicenter study, reviewed and confirmed by the FDA’s New Drug Application process, means this is an OTC topical analgesic that has the clinical proof and approval few have.

Strong Clinical Trial Results

40% Additional relief experienced with Salonpas® vs Placebo

58% Study patients rating satisfaction from Salonpas® as good/very good/excellent

From a randomized, double-blind, parallel-group, placebo-controlled, multicenter study1

Passed Rigorous FDA Review

<10% Less than 10% of OTC drug products have an NDA or have even been reviewed by the FDA

Salonpas® is the first OTC topical pain treatment to earn an NDA

The FDA’s New Drug Application (NDA) process is a rigorous process that every prescription medicine since 1938 has passed through.

Salonpas® is the first OTC labeled to treat both mild and moderate pain

Near-Zero Side Effects

.001% Rate of adverse events to Patch sales2

Long-Lasting, Controlled Dose

Treatment works locally, significant pain relief can start within 1 hour and lasts for up to 12 hours, with very little medicine traveling throughout the bloodstream. Some individuals may not experience pain relief until several hours after applying the patch.

For a published study reprint, please contact us using the button below.

Request a hard copy

  1. Higashi, etal Clinical Therapeutics/Volume 32, Number 1

  2. Based on reported adverse events between 2016-2020